
Mohummad Minhaj Siddiqui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4542670/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	lsolation of amniotic stem cell lines with potential for therapy. Nature Biotechnology, 2007, 25, 100-106.	17.5	1,739
2	Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390.	7.4	1,267
3	The use of whole organ decellularization for the generation of a vascularized liver organoid. Hepatology, 2011, 53, 604-617.	7.3	578
4	Magnetic Resonance Imaging/Ultrasound–Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy. European Urology, 2013, 64, 713-719.	1.9	436
5	Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer, 2013, 119, 3359-3366.	4.1	205
6	The Metabolic Phenotype of Prostate Cancer. Frontiers in Oncology, 2017, 7, 131.	2.8	164
7	A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncology, 2018, 4, 678.	7.1	141
8	Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e1-202.e7.	1.6	133
9	Diagnostic value of biparametric magnetic resonance imaging (<scp>MRI</scp>) as an adjunct to prostateâ€specific antigen (<scp>PSA</scp>)â€based detection of prostate cancer in men without prior biopsies. BJU International, 2015, 115, 381-388.	2.5	128
10	Whole organ decellularization - a tool for bioscaffold fabrication and organ bioengineering. , 2009, 2009, 6526-9.		90
11	Vasectomy and Risk of Aggressive Prostate Cancer: A 24-Year Follow-Up Study. Journal of Clinical Oncology, 2014, 32, 3033-3038.	1.6	46
12	Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule. Nature Medicine, 2005, 11, 95-101.	30.7	31
13	The Use of Multiparametric Magnetic Resonance Imaging (mpMRI) in the Detection, Evaluation, and Surveillance of Clinically Significant Prostate Cancer (csPCa). Current Urology Reports, 2019, 20, 60.	2.2	18
14	Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years. Journal of Urology, 2019, 201, 120-128.	0.4	13
15	The Use of Three-dimensional Visualization Techniques for Prostate Procedures: A Systematic Review. European Urology Focus, 2021, 7, 1274-1286.	3.1	12
16	PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 347-352.	3.9	12
17	Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 172-178.	3.9	11
18	MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up. Diagnostic and Interventional Radiology, 2021, 27, 394-400.	1.5	9

#	Article	IF	CITATIONS
19	Urologic Assessment of Decreasing Renal Function. Medical Clinics of North America, 2011, 95, 161-168.	2.5	7
20	Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer. Current Opinion in Oncology, 2020, 32, 223-231.	2.4	7
21	Urothelial Carcinoma. New England Journal of Medicine, 2018, 378, e8.	27.0	5
22	Injury severity score associated with concurrent bladder injury in patients with blunt urethral injury. World Journal of Urology, 2019, 37, 983-988.	2.2	4
23	Surgery associated with increased survival compared to radiation in clinically localized Gleason 9–10 prostate cancer: a SEER analysis. World Journal of Urology, 2021, 39, 415-423.	2.2	4
24	Performance of PI-RADS v2 assessment categories assigned prior to MR-US fusion biopsy in a new fusion biopsy program. Clinical Imaging, 2020, 64, 29-34.	1.5	3
25	National survey of practice patterns employing MRI-guided prostate biopsy for diagnosis of prostate cancer Journal of Clinical Oncology, 2017, 35, 104-104.	1.6	3
26	Hyperpolarized 13C magnetic resonance imaging, using metabolic imaging to improve the detection and management of prostate, bladder, and kidney urologic malignancies. Translational Andrology and Urology, 2018, 7, 855-863.	1.4	2
27	Litigation Patterns in Oncologic Nephrectomies: A 30-Year Review. Journal of Endourology, 2021, 35, 1158-1162.	2.1	2
28	Prediction of prostate cancer Gleason score using a MRI-based nomogram Journal of Clinical Oncology, 2014, 32, 255-255.	1.6	1
29	Twitter mentions and academic citations in the urologic oncology literature Journal of Clinical Oncology, 2017, 35, 70-70.	1.6	1
30	Con: Magnetic Resonance Imaging Targeting Leads to Overtreatment of Prostate Cancer. Journal of Urology, 2022, 208, 248-249.	0.4	1
31	Advances in the evaluation and management of lymph node involvement in urothelial carcinoma of the bladder. Expert Review of Anticancer Therapy, 2010, 10, 1855-1859.	2.4	0
32	Reply to D.C. Sokal et al. Journal of Clinical Oncology, 2015, 33, 670-671.	1.6	0
33	Vasectomy and risk of lethal prostate cancer: A 24-year prospective study Journal of Clinical Oncology, 2013, 31, 5086-5086.	1.6	0
34	Comparison of multiparametric MRI to PSA kinetics as an indication of prostate cancer progression in men on active surveillance Journal of Clinical Oncology, 2017, 35, 59-59.	1.6	0
35	Editorial Comment. Journal of Urology, 2018, 200, 1233-1234.	0.4	0
36	Validation of an artificial intelligence algorithm applied to a metabolic substrate analysis of urine for detection of urothelial cancer Journal of Clinical Oncology, 2019, 37, e16008-e16008.	1.6	0